Clinical trials · Washington, D.C., DC
Alzheimer’s disease clinical trials in Washington, D.C.
We’re tracking 30 recruiting alzheimer’s disease studies with a site in or near Washington, D.C. — including Phase 1, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT06976216RecruitingPhase 3
Study of KarXT plus KarX-EC for Alzheimer's cognitive symptoms
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
Washington D.C., District of ColumbiaAges 60–85 - NCT06416072Enrolling by invitation
Blood marker study for people not eligible for Alzheimer's prevention trials
This study looks at blood markers in people who were part of an early Alzheimer's prevention study but did not qualify for it because their amyloid levels were too low. It aims to understand brain changes and possibly find ways to detect Alzheimer's even earlier.
Washington D.C., District of ColumbiaAges 55–80 - NCT03702907Recruiting
Study of aging and a brain sample bank
This study follows adults as they age and may collect biological samples for future research. It could help researchers understand early and late changes related to aging and brain health.
Washington D.C., District of ColumbiaAges 45 years+ - NCT06808984RecruitingPhase 2
Testing a new drug for agitation in Alzheimer's disease
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
Washington D.C., District of ColumbiaAges 55–90 - NCT05010603Recruiting
Studies families to understand late-onset Alzheimer’s
This study focuses on people with late-onset Alzheimer’s (and some similar memory diseases) and uses a close family “informant” to share what they’ve noticed. It may help researchers learn more about these conditions and how they progress in families.
Washington D.C., District of ColumbiaAges 55 years+ - NCT05704309Enrolling by invitation
Study of diabetes prevention participants using brain scans
This study looks at how people who previously took part in a diabetes prevention program are doing over time, including brain health using MRI scans for some participants. It may help researchers understand who is at higher risk for memory and thinking problems and why.
Washington D.C., District of ColumbiaAges Any age - NCT05617014Enrolling by invitation
ADNI4 study for early Alzheimer’s with brain imaging tests
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
Washington D.C., District of ColumbiaAges 55–90 - NCT07717411RecruitingPhase 3
Trontinemab for people at risk of Alzheimer's symptoms
This study tests an investigational drug, trontinemab, in people who are cognitively healthy but have a blood marker suggesting a high chance of developing Alzheimer's symptoms later. The goal is to see if the drug can delay or prevent memory loss.
Arlington, VirginiaAges 55–80 - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Arlington, VirginiaAges 50–90 - NCT05980949RecruitingPhase 3
Long-term safety study of KarXT for Alzheimer's psychosis
This trial tests the long-term safety of an investigational drug called KarXT for people with psychosis caused by Alzheimer's disease. It is for those who have already completed a previous KarXT study and want to continue treatment.
Arlington, VirginiaAges 55–90 - NCT04396873RecruitingPhase 1
PET brain scan study of inflammation markers in neurodegeneration
This Phase 1 study tests a PET scan to measure inflammation-related changes in the brain using a medication called ketoprofen. It may help researchers understand which people with certain brain diseases could benefit from treatments aimed at inflammation.
Bethesda, MarylandAges 18–99 - NCT07169630RecruitingPhase 1
PET scan study for Alzheimer's or mild cognitive impairment
This study uses a special PET scan to look at a brain protein called PDE4 in people with Alzheimer's disease or mild cognitive impairment. It may help researchers understand how this protein is involved in memory and thinking problems.
Bethesda, MarylandAges 50–100 - NCT06585787RecruitingPhase 3
Testing KarXT for psychosis in Alzheimer’s disease
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
Vienna, VirginiaAges 55–90 - NCT07105709RecruitingPhase 2
Extension study for early Alzheimer's treatment
This study is a follow-up for people who completed a previous trial of an experimental treatment for early Alzheimer's disease. It will continue to test the treatment's safety and effects over a longer period.
Fairfax, VirginiaAges 50–85 - NCT06847321RecruitingPhase 2
Testing LHP588 for Alzheimer's linked to a mouth bacteria
This trial tests a new medication, LHP588, for people with Alzheimer's who also have a common mouth bacteria called P. gingivalis. The goal is to see if targeting this bacteria can help slow down memory loss.
Fairfax, VirginiaAges 55–80 - NCT06245031Enrolling by invitation
Long-term follow-up of sensory stimulation for Alzheimer's
This is a follow-up study for people who already completed the 12-month Hope Study (CA-0011). It tests long-term safety and effects of a gentle sensory stimulation device (light and sound) for Alzheimer's disease. You will continue using the device at home with a study partner.
Fairfax, VirginiaAges 50–92 - NCT07545577Recruiting
Training program for community health workers on dementia
This study tests whether online education about dementia helps community health workers better support people with dementia and their families. You'll complete online training and surveys to share what you learn.
Fairfax, VirginiaAges 18 years+ - NCT06159673RecruitingPhase 2/Phase 3
ACP-204 for Alzheimer's with psychosis
This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.
Gaithersburg, MarylandAges 55–95 - NCT06937229RecruitingPhase 3
Long-term study of KarXT for agitation in Alzheimer's
This trial tests if KarXT, taken with KarX-EC, is safe and effective for long-term treatment of agitation in Alzheimer's disease. It is for people who already completed a previous KarXT study.
Gaithersburg, MarylandAges 55–90 - NCT07011732RecruitingPhase 3
Testing a drug for Alzheimer's-related agitation
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
Gaithersburg, MarylandAges 55–90 - NCT07611396Recruiting
Study of brain changes in memory and thinking with aging
This study follows people with normal thinking, early memory problems, or Alzheimer's disease to understand how the brain changes over time. Researchers will use smell tests, blood work, and memory testing to learn more about these conditions and potentially help future treatments.
Germantown, MarylandAges 55 years+ - NCT03799991Recruiting
Balance therapy for people with early-to-moderate Alzheimer’s
This trial tests whether an 8-week balance and movement program can help people with early-to-moderate Alzheimer’s who also have inner-ear (vestibular) balance loss. You and a caregiver may learn exercises and attend weekly visits, while researchers compare the results to an active control program.
Baltimore, MarylandAges 60 years+ - NCT06930560Recruiting
Hearing aids for dementia with mood or behavior issues
This study tests whether providing hearing aids to older adults with Alzheimer's or related dementias can reduce troubling symptoms like agitation or depression. If you have untreated hearing loss and a caregiver who can join you, this trial may help improve quality of life.
Baltimore, MarylandAges 60–100 - NCT05795634Recruiting
Study stress effects in people at risk for Alzheimer’s
This study looks at how stress may affect thinking and memory in people with mild cognitive impairment (MCI) who are at risk for Alzheimer’s disease. You may be asked to do thinking tests and also involve a knowledgeable person who can report on changes over time.
Baltimore, MarylandAges 60 years+
Hear when a new Alzheimer’s disease trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Alzheimer’s disease trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting alzheimer’s disease studies listed above.
- Johns Hopkins University · 5 studies
- Georgetown University · 3 studies
- CBH Health LLC · 2 studies
- Howard University · 2 studies
- National Institutes of Health Clinical Center · 2 studies
- Re:Cognition Health · 2 studies
- Sana Research, LLC · 2 studies
- Biostatistics Center, George Washington University
What taking part in a alzheimer’s disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting alzheimer’s disease studies in District of Columbia.
Common questions
- Are there alzheimer’s disease clinical trials near Washington, D.C.?
- Yes. We're currently tracking 30 recruiting alzheimer’s disease studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a alzheimer’s disease study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a alzheimer’s disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New alzheimer’s disease studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.